Featured Products

In our efforts to keep you informed of all developments within the R&D community, here is our most recently featured products:

Vilazodone CAS# 163521-12-8

Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year. The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. LGM Pharma is hot on the tracks of this new drug development. Since gaining approval, LGM Pharma has become the preferred supplier of Vilazodone by pharmaceutical companies who are currently engaged in its R&D...

Read More >
Inquire about Vilazodone >

Docetaxel CAS# 114977-28-5

A recent study conducted by the Queen's University Belfast's School of Pharmacy revealed the ability of the recombinant protein FKBPL to inhibit tumor growth by disrupting the blood supply to these tumors. One such study employed recombinant FKBPL (rFKBPL) both singly and in combination with docetaxel, an antimitotic agent also commonly employed in ovarian and breast cancer therapy. The results showed significant antiangiogenic activity when tested on human tumor xenograft models...

Read More >
Inquire about Docetaxel >

Disclaimer: Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Recent Blog Posts

Levocloperastine Fendizoate: The Better Antitussive Agent Over Codeine Posted on: 5/5/11 Many of the antitussive agents available in the market today act on the CNS and cause the adverse events mostly associated with them such as sedation, vomiting, and nausea. One in particular, codeine, can lead to drug dependence. Because of this, pharmaceutical companies were prompted to develop a peripherally-acting antitussive agent that minimizes these central adverse effects. The endeavor resulted in a new research molecule... More > Bazedoxifene Proven Safe and Effective For Women At Risk For Osteoporosis Posted on: 5/2/11 A clinical study spanning two years investigated the effects of the drug Bazedoxifene (Conbriza) at 10, 20 and 40 mg on postmenopausal women at risk for osteoporosis. The results showed positive indications for preventing bone loss and reducing bone turnover. What's more is that the study demonstrated the drug's safety profile and its use is not associated with endometrial, ovarian, and breast malignancy risks.... More >